SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other EventsItem 8.01 Other Events
On February 5, 2018, Second Sight Medical Products, Inc. issued a press release which provided an update, as of January 31, 2018, on several key performance metrics, demonstrating the Company’s continued progress in executing its near- and long-term goals. These are outlined below.
Business Highlights as of January 31, 2018:
| ● | Implanted 30 Argus® II Retinal Prosthesis Systems worldwide during the fourth quarter of 2017, for a total of 75 implants in 2017. This compares to seven implants in the fourth quarter of 2016, and a total of 42 implants in 2016, representing implant volume growth of 329% and 79%, respectively; |
| ● | The first human patient was implanted with the Orion™ Cortical Visual Prosthesis System (Orion) by Nader Pouratian, MD, PhD, Vice Chairman of the Department of Neurosurgery at the Ronald Reagan UCLA Medical Center (UCLA) in late January as part of Second Sight’s feasibility clinical study; |
| ● | Enrollment of the first patient(s) is expected during Q1 2018 in a clinical study of better-sighted patients with Retinitis Pigmentosa (RP) in Germany. Two sites are actively screening subjects with a third site to begin screening shortly; |
| ● | Added a new Center of Excellence in Houston, TX in early January, further validating the success of the Company’s business model that emphasizes close partnering with implanting sites; and, |
| ● | Reimbursement for the Argus II in Germany was renewed for the 2018 calendar year, marking the eighth year that Argus II implants have been reimbursed through the NUB program. |
A copy of our press release entitled “Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant” is attached as Exhibit 99.1 to this Current Report on Form 8-K, and the description above is qualified in its entirety by reference to this release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release issued February 5, 2018 |
SECOND SIGHT MEDICAL PRODUCTS INC ExhibitEX-99.1 2 s108983_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant SYLMAR,…To view the full exhibit click here
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
